- A poster presentation at ASH shows Ligand Pharmaceuticals' (LGND) G-CSF receptor agonist LGD-455 "significantly increases peripheral blood neutrophils, inhibits tumor cell growth and increases apoptosis."
- The company evaluated the treatment's ability to stimulate white blood cell counts in cynomolgus monkeys. (PR)
Preclinical studies for Ligand's G-CSFR agonist presented at ASH
Dec 9 2013, 08:03 ET